What does a breakout company like Moderna do for an encore? More than a decade after its founding, the Cambridge biotech rolled out its first commercial product last year. And what a debut it was: a cutting-edge COVID-19 vaccine that helped to save thousands ― if not millions ― of lives around the world.
It was also a massive moneymaker for Moderna, which up until then had been unprofitable. With more than $38 billion in total COVID-19 vaccine sales expected by the end of this year ― many of the doses paid for by governments ― investors are wondering what the company plans to do with that windfall. Despite Moderna’s spectacular success, the question of what’s next looms large, and the pressure is on to avoid becoming a one-hit wonder.
Create a display name to comment
This name will appear with your comment
